



SEMPERIT GROUP FY 2022 INVESTOR PRESENTATION

Karl Haider, CEO

Helmut Sorger, CFO

22 March 2023



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.23)

Appendix (p.26)



Strategic and operational highlights FY 2022



Sale of Sempermed to HARPS announced on 16 December 2022; sales price of EUR 115m; completion of first part (examination gloves) expected mid-year; second part (surgical gloves) remains up to five years as contract manufacturing



Change in reporting according to IFRS 5: Split into
- continued (Industry & Medical/surgical) and
- discontinued (Medical/exam) operations



Industrial Sector with significant increase in sales and earnings against the backdrop of lower order intake and high inflation



Proposed base dividend of EUR 1.50 per share and conditional special dividend between EUR 2.00 and 3.50 depending on the sale of Sempermed and further organic and inorganic growth activities



Continuing implementation of industrial elastomer strategy with strong momentum in organic and inorganic growth





Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)


Outlook (p.23)

Appendix (p.26)




Industrial Sector: significant sales and earnings increase

Revenues in EUR m FY'19 – FY'22



Quarterly development of EBITDA (EURm) and EBITDA margin (%)




- Outstanding Industrial Sector performance on the back of high order book and proactive and timely price increases, notably Semperflex, as well as late-cycle upswing at Sempertrans
- Against the backdrop of economic slowdown and consistently high inflation: active price policy and disciplined cost management to offset margin pressure
- Softening demand combined with customer inventory clean-up following different cycles across various segments




Semperflex FY 2022

Lower customer demand and economic slowdown started in Q3'2022

Semperflex



FY 2022 vs. FY 2021



- Sales up by 36.7% and EBITDA by 60.1% yoy, largely on the back of strong demand in H1'2022 and output increases in all other Semperflex plants except China
- Higher volumes, efficiency enhancement and timely price adjustments offset higher costs of raw materials, transport, energy and personnel
- Q3'2022 marked a turning point in customer demand including inventory clean-up despite easing of price pressure for raw materials, energy and transport







Sempertrans FY 2022

Late-cycle tailwinds resulted in highest order book for last three years

Sempertrans



FY 2022 vs. FY 2021



- Strong demand for mining increased demand for steel and textile belts used especially mining industry for 2022
- Sales up by 45.5% and EBITDA by three times yoy, including the asset sale of closed factory in France for EUR 4.7mn
- Higher volumes and price increases offset input costs and deconsolidation effect of EUR 3.7mn due to FX differences after closing of Sempertrans affiliate in China in 2021



¹ Q1'19 EBITDA: positive effect of EUR 1.3m profit from sale of assets of closed factory in China

² Q3'21 EBITDA: positive effect of EUR 3.7m from recycling of foreign exchange differences



³ Q4'22 EBITDA: positive net effect of EUR 4.7m from sale of property in connection with factory closure in France in 2018




Sempersal FY 2022

Impact of economic slowdown in construction since Q4'2022


Sempersal



FY 2022 vs. FY 2021



- Clear slowdown in demand since Q4'2022 resulted in lower orders compared to end-2021
- Top-line growth of 17.9% yoy thanks to good start in H1'2022 and various price increases
- Inflationary pressure on input costs could only be passed on with time lag while results additionally impacted by EUR 2.1mn impairment of machines and equipment in Q3'2022
- First production line in Newnan, Georgia (USA) started in Q1'2022 and second line in July 2022








Semperform FY 2022

Results impacted by price increases and changed product mix

Semperform



FY 2022 vs. FY 2021



- Order book still up in 2022 but backlog slightly down due to strong pent-up demand in previous period
- Consistent price increases and changed product mix led to 22.7% top-line growth, offsetting higher input costs in Q2-Q3'2022 and keeping margins stable
- Strong performance by BU Special Applications (recovery of winter tourism) compared with lower demand in Engineered Solutions (railways and white goods)







Medical Sector / Sempermed segment FY 2022

Excess capacity, reduced demand and further inventory clean-up impact volumes

Sempermed



FY 2022 vs. FY 2021



- With market prices being significantly down since Q2'2022 sales volumes declined rapidly, aggravated by excess capacity, falling demand and very high customer inventories in the entire industry
- EBITDA impacted by high costs of raw materials, logistics, energy and personnel, notably in Malaysia since Q2'2022 as well as provisions (e.g. gas contracts, inventory)
- Impairment of EUR 51.6mn in Q3'2022 offset by reversal of EUR 40.9mn due agreement reached in Q4'2022 on the sale of Sempermed



¹ Q3'19 EBITDA adjusted for EUR 4m due to the positive effect from the release of provision in Sempermed for Brazilian court case for tax liabilities

² Q4'22 EBITDA includes transaction costs of EUR 8.4m as a result of the agreed sale of Sempermed



Medical Sector – Sales agreement with HARPS

- Signing on 16 December 2022: Sale of medical business agreed with the Southeast Asian glove producer HARPS GLOBAL PTE. LTD., based in Singapore with production facilities in Malaysia
- The sales price (cash and debt free) is EUR 115 million and is subject to customary price adjustment mechanisms upon completion of the transactions
- The execution of the transaction is subject to the approval of the authorities
- Deal structured in two stages:
 - First closing: production of examination gloves in Malaysia along with the associated sales and distribution units worldwide expected by mid-2023 concerning
 - Second closing: production of surgical gloves in Wimpassing, Austria, and their packaging in Sopron, Hungary, will continue to be commissioned for HARPS by the Semperit Group under a contract manufacturing agreement for up to five years until the sale is finalised
- Sempermed management dedicated to transfer to new owner



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.23)

Appendix (p.26)



CFO focus and financial framework



Financial framework

- Disciplined cash management
- Strong financial position with healthy leverage
- Efficient capital allocation: balanced focus on growth and sustainable shareholder return
 - Disciplined growth investments with strict return criteria
 - Attractive dividend policy



Strategic focus:

- Financial steering of the business
 - Stewardship of medical business
 - Ensure an efficient capital structure going forward



Operational focus

- Digitalisation
- Simplification and lean enterprise (incl. future efficiency enhancement)
- Stringent Working Capital management remains key
- Focus on cost control and adjustment of overhead base according to the needs of the group setup






IFRS 5 Effects:

Profit and Loss

Sales, EBITDA, EBIT, financial results – shown for continued operations

Net result after tax – shown separately for continued and discontinued operations and on aggregate

1. EBITDA before the transaction



2. EBITDA continued operations



EBITDA discontinued operations



Balance Sheet

Reclassification impacted positions to assets, provisions and liabilities held for sale

















Cashflow

Reflects cash development of continued and discontinued business

Details shown for continued operations (primaries & relevant notes) and also for discontinued operations under note 2.9 of the Annual Report 2022




Overview of key financial KPIs, 2021 vs. 2022 (as reported)

	FY 2021	FY 2022	Δ '21/'22
Revenues, in EUR m	 601.8	 779.8	↗ 29.6%
EBITDA, in EUR m	 54.0	 100.5	↗ 86.2%
EBITDA margin, in %	 9.0	 12.9	↗ 3.9PP
EBIT, in EUR m	 25.2	 62.1	↗ 146.3%
EBIT margin, in %	 4.2	 8.0	↗ 3.8PP
Earnings after tax, in EUR m	 247.5	 -5.6	↘ n.m.
Free Cashflow, in EUR m	 241.2	 0.0	↘ n.m.
CAPEX, in EUR m	 47.9	 54.5	↗ 13.8%



Revenue: Segment reporting & reconciliation for continued business




% change of each segment / sector refers to 2022 vs. 2021.

¹Sales between continued and discontinued business



Strong performance in Industrial against steep decline in Medical

in EUR m




	FY 2021	Semperflex	Sempertrans	Semperséal	Semperform	Sempermed	Corporate	FY 2022 = Segments' Total = "as-if" no transaction	Adjustments on Group level	Continued and discontinued operations	Discontinued operations	Continued operations
EBITDA FY 2021	361.8	51.3	6.8	11.6	12.4	301.1	-21.8					
EBITDA FY 2022		82.2	19.7	8.3	15.1	-15.4	-19.3	90.4				
margin FY 2022		25.0%	12.9%	5.8%	13.6%	-4.7%	-	8.6%				



Major drivers of operating performance

in EUR million






Quarterly Segment CAPEX development 2021-2022

- FY2022 CAPEX above prior-year level
- Industrial continues to receive higher CAPEX, notably Semperflex and Semperseal
- Responsible stewardship for Sempermed with continuing CAPEX in Q4'2022
- FY2023 maintenance CAPEX to remain stable at EUR ~50m and an additional EUR ~50m planned for growth investments (DH5)

CAPEX per segment


in EUR m





Free cash flow development

- Operating cash flow
 - Significantly reduced due to lower earnings and EUR 62.1mn tax payment, notably at Sempermed
 - Impacted by inventory build-up
- Investment cash flow: largely stable
- After years of being reduced to necessary levels CAPEX normalized with stronger focus on organic growth in addition to maintenance CAPEX






Working Capital overview

Components of Working Capital

in EUR m



Trade Working Capital in % of LTM revenues;


¹ 31. Dec 2022 without disposal group Sempermed, all historical values in total; TWC of discontinued operations at EUR 36.3m (thereof inventories at EUR 38.6m, trade receivables at EUR 17.5m and trade payables at EUR 19.8m); 11.2% of LTM revenues



Balance sheet structure and financial profile (contd. operations)

Balance sheet structure

Balance sheet 31/12/2022: EUR 843m
Balance sheet 31/12/2021: EUR 959m



Financial profile as of 31 December 2022

- **Cash and cash equivalents** at EUR 107m – Strong cash position to fend off inflationary impact and keep powder dry for M&A
- **Available credit facilities** total EUR 90m
- **Corporate Schuldschein loan** at EUR 52m
- **“Net debt” remains net cash** at EUR 54m, Net debt / EBITDA below zero (YE’21: below zero)
- **Equity ratio** of 61.5% (YE’21: 56.3%)
- **Dividend Proposal** for base dividend of EUR 1.50 per share (to be paid in May 2023) and conditional additional dividend of EUR 2.00 to EUR 3.50 for 2022 (to be paid in Q4 2023)



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.23)

Appendix (p.26)



Management agenda 2023



Starting point in early 2023

Operations:

Encouraging start in Industrial Sector...

...while Medical Sector burdened by high inventory level in the market

Diminished recessionary fears albeit market slowdown in economic activity and continuing high inflation (high inventories in the supply chain)

Growing price sensitivity and ongoing cost pressure, notably for personnel and possibly for energy and raw materials

Strategy:

Continuing implementation of industrial elastomer strategy with new momentum for organic and inorganic growth

Sale of medical business signed:

first step (examination gloves) expected to be completed by mid-year

second step (surgical gloves) to remain with Semperit for up to five years as contract manufacturing



Outlook 2023 (continued operations)



EBITDA in the range of 70–90m EUR

CAPEX ~ 100 m EUR for 50:50 growth and maintenance

Base dividend 2022 at EUR 1.50 per share

Conditional dividend to be announced before AGM



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Am Belvedere 10
1100 Vienna, Austria

Financial Calendar 2023

22.03.2023	Publication of 2022 annual financial statements
25.04.2023	Annual General Meeting, Vienna
10.05.2023	Report on Q1 2023
10.08.2023	Half-year financial report 2023
08.11.2023	Report on Q1-3 2023

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.23)

Appendix (p.26)



Sectors and Group: FY 2022 vs FY 2021

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	FY 2022 ¹	FY 2021	%	FY 2022 ¹	FY 2021	%	FY 2022 ¹	FY 2021	%
Revenue	734,0	556,1	+32,0%	324,2	626,1	-48,2%	1 058,2	1 182,2	-10,5%
EBITDA	125,2	82,1	+52,5%	-15,4	301,1	n/a	90,5	361,8	-75,0%
EBITDA margin	17,1%	14,8%	+2,3 PP	-4,7%	48,1%	-52,8 PP	8,6%	30,6%	-22,1 PP
Adj. EBITDA	120,5	82,1	+46,8%	-7,0	301,1	n/a	94,1	63,8	+47,6%
Adj. EBITDA margin	16,4%	14,8%	+1,7 PP	-2,2%	48,1%	50,3 PP	8,9%	7,6%	+1,3 PP
EBIT	95,9	56,8	+68,9%	-49,5	280,9	n/a	25,8	315,0	-91,8%
EBIT margin	13,1%	10,2%	+2,9 PP	-15,3%	44,9%	-60,1 PP	2,4%	26,6%	-24,2 PP
Adj. EBIT	93,4	56,8	+64,4%	-36,9	280,9	n/a	42,3	315,0	-86,6%
Adj. EBIT margin	12,7%	10,2%	+2,5 PP	-11,4%	44,9%	-56,3 PP	4,0%	26,6%	-22,6 PP
Earnings after tax from continued operations	–	–	–	–	–	–	38,4	3,6	>100%
Earnings after tax from discontinued operations	–	–	–	–	–	–	-44,0	243,9	>100%
Earnings after tax	–	–	–	–	–	–	-5,6	247,5	>100%
Earnings after tax adjusted	–	–	–	–	–	–	10,9	247,5	-95,6%
Earnings per share in EUR	–	–	–	–	–	–	-0,3	12,0	n.a.
Additions in tangible and intangible assets	32,2	28,7	+12,0%	15,0	24,9	-39,7%	50,1	56,4	-11,2%
Employees	3 821	3 764	+1,5%	2 597	3 038	-14,5%	6 528	6 948	-6,1%

¹¹ Industrial Sector adjusted for the positive one-off effect of the net proceeds from the property of land in France in the Sempertrans segment (2022: EBITDA and EBIT effect: EUR –4.7 million) and for the negative one-off effect from the impairment in the Semperseal segment (2022: EBIT effect: EUR -2.1 million); Medical Sector adjusted for the one-off effect of the negative effect of the net impairments in the Sempermed segment (2022: effect on EBIT: EUR –10.8 million) and the one-off effect of the transaction costs (2022: effect on EBITDA and EBIT: EUR 8.4 million); Group EBITDA and EBIT shown as if no transaction has (yet) taken place; Adjusted for the positive one-off effect of the net proceeds from the sale of property in France in the Sempertrans segment (2022: effect on EBITDA and EBIT: EUR 4.7 million) and for the negative one-off effect of the net impairments in the Sempermed and Semperseal segments (2022: effect on EBIT: EUR –12.9 million) and negative effect of the transaction costs (2022: effect on EBITDA: EUR –8.4 million); EAT (cfd. + discd.) adjusted for the positive one-off effect of the net proceeds from the sale of properties in France in the Sempertrans segment (2022: EUR 4.0 million), for the negative effect of the net impairments in the Sempermed and Semperseal segments (2022: EUR –12.3 million) and for the negative effect of the transaction costs (2022: EUR –8.2 million)




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 adj.	FY 2020 adj. ³⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ⁴⁾	Q4 2022 adj. ⁵⁾	FY 2022 adj. ⁵⁾
Revenue	840.6	199.1	219.8	238.2	270.5	927.6	323.1	337.7	265.3	256.1	1,182.2	277.0	293.6	259.0	228.6	1,058.2
EBITDA	63.8	16.9	40.7	60.9	90.0	208.6	122.2	125.3	76.8	37.5	361.8	36.5	38.7	10.7	8.3	94.1
EBITDA margin	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%	37.1%	28.9%	14.6%	30.6%	13.2%	13.2%	4.1%	3.6%	8.9%
EBIT	28.2	9.8	33.6	49.2	78.8	171.4	110.8	113.8	65.4	25.0	315.0	23.7	24.7	-3.5	-2.6	42.3
EBIT margin	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%	33.7%	24.7%	9.8%	26.6%	8.6%	8.4%	-1.4%	-1.1%	4.0%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) ²⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ³⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million) ⁴⁾ Q3 2022: adjusted for the negative one-off effect of the impairments in segments Sempermed and Semperseal (Q3 2022: EBIT effect EUR -53.9 million, earnings after tax EUR -53.9 million). ⁵⁾ numbers refer to segment view, as if no separation has taken place; 2022 adjusted for the positive one-off effect of the net proceeds from the sale of property in France in the Sempertrans segment (2022: effect on EBITDA and EBIT: EUR 4.7 million) and for the negative one-off effect of the net impairments in the Sempermed and Semperseal segments (2022: effect on EBIT: EUR –12.9 million) and negative effect of the transaction costs (2022: effect on EBITDA: EUR –8.4 million).



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
in EUR m																
Revenue	222.7	46.8	51.5	46.6	45.0	189.9	54.7	59.7	57.7	68.4	240.5	79.8	93.9	78.5	76.6	328.8
EBITDA	47.9	9.3	14.0	11.4	7.2	41.9	12.3	13.9	11.2	13.9	51.3	19.6	27.3	21.5	13.9	82.2
EBITDA margin	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%	23.3%	19.3%	20.4%	21.3%	24.5%	29.0%	27.3%	18.1%	25.0%
EBIT	36.0	6.5	11.2	8.7	4.5	30.9	9.6	11.1	8.4	11.0	40.0	16.6	24.3	18.5	10.8	70.2
EBIT margin	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%	18.5%	14.5%	16.1%	16.6%	20.8%	25.8%	23.6%	14.1%	21.4%

Sempertrans (Conveyor belts)

	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 ³⁾	FY 2020 adj. ⁴⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022 adj. ⁵⁾	FY 2022 adj. ⁵⁾
in EUR m																
Revenue	134.0	29.5	32.5	28.4	22.7	113.1	26.9	24.2	28.0	25.3	104.5	28.3	41.5	40.0	42.1	151.9
EBITDA	13.5	1.6	5.0	2.1	0.0	8.7	1.0	0.8	4.7	0.4	6.8	1.3	5.3	3.7	4.7	14.9
EBITDA margin	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%	3.3%	16.7%	1.4%	6.6%	4.5%	12.9%	9.2%	11.2%	9.8%
EBIT	8.9	0.6	3.9	1.4	-0.6	4.9	0.2	-0.1	3.8	-0.7	3.2	0.3	4.4	2.6	3.6	10.8
EBIT margin	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%	-0.2%	13.6%	-2.9%	3.1%	1.2%	10.5%	6.5%	8.5%	7.1%

¹⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect: EUR 20.0 million).

²⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

³⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁴⁾ 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)

⁵⁾ Q4 2022 and 2022: adjusted for the the positive one-off effect of the net proceeds from the sale of property in France in the Sempertrans segment (2022: EBITDA and EBIT effect: EUR -4.7 million).



Semperform and Semperséal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - after 2020

	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
in EUR m																
Revenue	91.1	19.9	21.9	20.4	19.6	81.8	19.8	23.6	23.3	23.9	90.6	26.2	27.5	29.3	29.3	111.1
EBITDA	15.6	3.5	5.0	4.0	2.5	15.0	3.1	3.6	3.3	2.5	12.4	3.2	5.0	4.1	4.1	15.1
EBITDA margin	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%	15.2%	14.1%	10.3%	13.7%	12.2%	18.3%	13.9%	13.9%	13.6%
EBIT	12.0	2.6	4.1	3.1	1.6	11.3	2.1	2.6	2.3	1.4	8.5	2.1	4.0	3.0	3.0	10.8
EBIT margin	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%	11.2%	10.0%	6.0%	9.4%	8.2%	14.4%	10.3%	10.3%	9.7%

Semperséal (Profiles and Rubber Sheeting) starting in 2020

	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ¹⁾	Q4 2022	FY 2022
in EUR m																
Revenue	99.5	25.4	21.7	24.4	22.2	93.6	28.7	30.3	32.4	29.1	120.5	36.6	38.4	38.3	28.8	142.1
EBITDA	10.4	3.3	3.2	2.9	1.7	11.0	4.2	2.4	4.1	0.9	11.6	2.4	3.9	3.2	-1.2	8.3
EBITDA margin	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%	7.9%	12.6%	3.0%	9.6%	6.5%	10.1%	8.3%	-4.1%	5.8%
EBIT	4.0	1.8	1.7	1.4	0.2	5.1	2.6	0.8	2.5	-0.9	5.1	0.5	2.3	-0.6	-2.9	-0.6
EBIT margin	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%	2.6%	7.7%	-3.1%	4.2%	1.4%	5.9%	-1.4%	-9.9%	-0.4%

¹⁾ Adjusted for the negative one-off effect of the impairment in the segment Semperséal (Q3 2022 and FY 2022: EBIT effect: EUR -2,1 million).

Split of former Semperform into Semperséal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)

in EUR m	FY 2019 ¹⁾	Q1 2020	Q2 2020 adj. ²⁾	Q3 2020 adj. ³⁾	Q4 2020 ⁴⁾	FY 2020 adj. ⁵⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ⁶⁾	Q4 2022 adj. ⁷⁾	FY 2022
Revenue	293.3	77.5	92.2	118.4	161.1	449.2	192.9	199.8	124.0	109.4	626.1	106.1	92.3	72.9	-225.4	324.2
EBITDA	1.4	4.8	18.2	44.4	83.0	150.4	105.3	115.3	56.9	23.7	301.1	13.3	2.3	-19.6	-3.8	-15.4
EBITDA margin	0.5%	6.1%	19.7%	37.5%	51.5%	33.5%	54.6%	57.7%	45.9%	21.7%	48.1%	12.6%	2.5%	-26.9%	1.7	-4.7%
EBIT	-5.5	4.4	17.6	38.9	77.8	138.7	100.2	110.3	52.1	18.3	280.9	7.6	-4.7	-78.5	13.9	-36.9
EBIT margin	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%	52.0%	55.2%	42.0%	16.7%	44.9%	7.2%	-5.1%	-107.6%	-6.2	-11.4%

¹⁾ 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

²⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

³⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁴⁾ Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁵⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)

⁶⁾ Q3 2022: adjusted for the negative one-off effect of the impairment in the segment Sempermed (Q3 2022: EBIT effect: EUR -51,8 million).

⁷⁾ Q4 and 2022: Adjusted for the one-off effect of the negative effect of the net impairments in the Sempermed segment (2022: effect on EBIT: EUR -10.8 million) and the one-off effect of the transaction costs (2022: effect on EBITDA and EBIT: EUR 8.4 million).



Key figures 2012-2022

Key performance figures											
in EUR m	2012	2013	2014 ¹⁾	2015 ¹⁾	2016 adj. ²⁾	2017 adj. ³⁾	2018 adj. ⁴⁾	2019 adj. ⁵⁾	2020 adj. ⁶⁾	2021	2022 ⁷⁾
Revenue	828,6	906,3	858,3	914,7	852,4	874,2	878,5	840,6	927,6	1 182,2	1 058,2
EBITDA	108,7	132,5	101,9	96,2	74,7	35,8	50,3	63,8	208,6	361,8	90,5
EBITDA margin	13.1%	14.6%	11.9%	10.5%	8,8%	4,1%	5,7%	7,6%	22,5%	30,6%	8,6%
EBIT	72,5	87,8	63,8	66,7	41,1	-0,8	15,4	28,2	171,4	315,0	25,8
EBIT margin	8.8%	9.7%	7.4%	7.3%	4,8%	-0,1%	1,7%	3,6%	18,5%	25,6%	2,4%
Earnings after tax	46,2	54,9	37,8	46,4	15,2	-43,9	-17,3	-0,2	121,9	247,5	-5,6
EPS, in EUR	2,25	2,65	1,85	2,26	0,74	-2,08	-1,06	-0,33	5,53	11,99	-0,27
Gross cash flow	85,6	116,2	89,9	55,7	48,1	32,2	37,4	46,70	193,7	323,4	30,5
Return on equity	11.4%	13.3%	8.6%	12.8%	4,6%	-15,8%	-4,2%	-16,3%	58,0%	45,7%	-1,1%


Balance sheet key figures											
in EUR m	2012	2013	2014 ²⁾	2015 ²⁾	2016	2017	2018	2019	2020	2021	2022 ⁷⁾
Balance sheet total	824,5	852,1	826,3	937,8	1034,5	853,2	768,8	701,8	764,4	958,6	842,9
Equity	406,2	411,5	443,8	363,3	329,3	278,5	329,5	237,4	332,3	540,1	518,2
Equity ratio	49.3%	48.3%	53.7%	38.7%	31.8%	32,6%	42,9%	39,0%	43,5%	56,3%	61,5%
Investments in tangible and intangible assets	41,2	49,7	67,4	71,8	65,1	74,5	80,8	31,9	26,4	56,4	50,1
Employees, at balance sheet date, FTEs	9 577	10 276	6 888	7 053	6 974	6 838	6 773	6 902	6 943	6 948	6 528

¹⁾ 2014 and 2015 restated. ²⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ³⁾ 2017 adjusted for positive one-off effects from JV transaction of EUR 85m (EUR 65m for net profit) and negative one-off effects from impairment at Sempermed (EUR 26m adj. EBIT, EAT only), from restructuring expenses in France (EUR 11m), valuation adjustment in IT (EUR 4m EBITDA, EUR 3m EBIT) and expenses resulting from tax audit in Austria (EUR 5m, mainly for refund of energy supply charge). ⁴⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4m for EBITDA, EUR 8m for EBIT and EAT) and for impairment of Sempermed of EUR 55m (adj. for EBIT and EAT only). ⁵⁾ FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁶⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million); ⁷⁾ 2022 EBITDA & EBIT: as if no separation has taken place, segment view; balance sheet according to IFRS 5, with reclassifications



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable





¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment view, FY 2022

in EUR m

Semperit Group

	Industrial Sector				Medical Sector ⁴⁾
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed
Revenue	328.8 / 31% ¹⁾	151.9 / 14% ¹⁾	111.1 / 10% ¹⁾	142.1 / 13% ¹⁾	324.2 / 30% ¹⁾
EBITDA	82.2	19.7	15.1	8.3	-15.4
Employees	1,782 / 27% ³⁾	889 / 13% ³⁾	591 / 9% ³⁾	560 / 9% ³⁾	2,597 / 40% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe
6 position globally



Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of polymer and plastics
(**handrails, cable car rings, ski foils and Engineered Solutions**)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting
(**construction, packaging, machinery, HVAC, marine, electric systems**)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe




*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.
³⁾ Employees in % of Group employees.
Figures refer to segment view.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from supportive ownership structure with long-term commitment from B & C